Menu
Recruiting NCT07379476

Local Ablative Therapy to Oligoresidual Metastasis in EGFR Mutated Non-small Cell Lung Cancer

Phase II Interventional Lung Cancer (NSCLC)

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Local ablative therapy, Osimertinib alone.
Who it may be relevant to
Registry conditions: Lung Cancer (NSCLC). Basic parameters: from 18 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Hong Kong
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Official title

ATOM2: A Randomized Phase II Trial on Ablative Therapy to Oligoresidual Metastasis in EGFR Mutated Non-small Cell Lung Cancer After Osimertinib Treatment

Overview

This is an open-label, multicentre, randomized phase II clinical trial. Patients with stage IV (AJCC 9th edition) non-small cell lung cancer (NSCLC) harboring EGFR exon 19 deletion or exon 21 L858R mutation, who had less than or equal to 3 active oligoresidual cancer sites amenable to local ablative therapy (LAT) (as determined by physician) after 3-6 months of firstline osimertinib treatment, are eligible. Subjects will be randomized 1:1 to osimertinib with or without LAT.

Interventions

  • Radiation Local ablative therapy
    Local ablative therapy (LAT) will be given in the form of stereotactic body radiotherapy (SBRT) or hypofractionated radiotherapy. LAT should be started within 90 days from the screening PET-CT scan.
  • Drug Osimertinib alone
    Continue osimertinib as per standard of care (40mg or 80mg daily)

Primary outcome measures

  • 18 month progression-free survival rate (PFS) in per-protocol population as determined by investigator. [Time frame: up to 2 years]
Secondary outcome measures (4)
  • Overall survival (OS) [Time frame: 2 years]
  • Safety and tolerability reflected by number of participants with treatment related adverse events as assessed by CTCAE v5.0, number of participants with SAE [Time frame: 2 years]
  • Time to treatment failure (TTF), defined as the time period between osimertinib initiation and cessation or death [Time frame: 2 years]
  • Site of tumour progression at disease progression [Time frame: 2 years]

Eligibility criteria

Inclusion criteria

  • 18 years of age or older and able to understand and give written informed consent
  • Pathologically proven non-small cell lung cancer
  • Positive for EGFR exon 19 deletion or EGFR exon 21 L858R mutation (either by tissue or plasma testing)
  • Stage IV disease
  • Receive first line osimertinib monotherapy for stage IV disease
  • Undergo a PET-CT scan after 12-24 weeks of initiation of osimertinib treatment, with no evidence of disease progression, and less than or equal to 3 active disease sites (including primary tumour) amenable to local ablative therapy, as determined by investigator
  • At least one brain imaging (CT Brain or MRI Brain with contrast, preferably MRI Brain), either at time of diagnosis or while on osimertinib treatment but before randomization, to document CNS status for stratification. Patients with asymptomatic CNS metastases are eligible. For patients with brain metastases diagnosed at baseline, follow up brain imaging is recommended before randomization.
  • Patients with history of palliative radiotherapy are eligible
  • Eastern Cooperative Oncology Group (ECOG) performance status 0-1
  • Adequate haematological values: haemoglobin ≥9.0g/dL, absolute neutreophil count ≥1.0 x 109/L, platelet count ≥100 x 109/L
  • Adequate hepatic function: bilirubin ≤1.5 x ULN, AST/ALT ≤2.5 x ULN
  • Adequate renal function: creatinine clearance ≥30ml/min, according to the formula of Cockcroft-Gault equation
  • Willing and able to comply with the requirements and restrictions in this protocol

Exclusion criteria

  • Previous or concomitant malignancy within 5 years prior registration with the exception of adequately treated localized non-melanoma skin cancer or cervical cancer in situ.
  • Mixed SCLC and NSCLC histology
  • Positive pregnancy test
  • Contraindication to radiotherapy
  • Any serious underlying medical, psychiatric, psychological, familial condition that in the judgement of the investigator, that may interfere with planned staging, treatment and follow up, affect patient compliance, or place the patient at high risk from treatment related complications

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
Randomized
Model
Parallel assignment
Masking
Open label
Primary purpose
Treatment

Study locations

Hong Kong · 1 center
  • Department of Clinical Oncology, Prince of Wales Hospital — Hong Kong

Identifiers

NCT: NCT07379476 · LUN126

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗